Abstract
Overview
Introduction
Female sexual dysfunction (FSD) affects an estimate 84 million women across
the seven major pharmaceutical markets and represents a significant
opportunity for investment. Despite its high prevalence, FSD is poorly
understood and defined. Currently there is just one product approved for the
treatment of FSD; P&G' s Intrinsa (testosterone) is marketed in Germany, France
and the UK.
Scope
- Comprehensive overview of the FSD pipeline with focus on clinical
candidates in development for FSD
- Analysis of the latest clinical trials results of FSD drug candidates in
Phase I to III development
- Analysis of the challenges and opportunities facing products in Phase III
and above with estimates of launch dates.
- Separation of drugs in development for different patient segments
including hypoactive sexual desire disorder and female sexual arousal disorder
Report Highlights
Despite the relatively large patient population, currently there is just one
approved drug treatment for FSD. There is much unmet need among patients and
physicians and consequently Datamonitor believes there is an opportunity to
develop this market to parallel to that of the multi-billion dollar male
erectile dysfunction market
While Intrinsa has benefited from first-to-market advantage, the drug suffers
from several weaknesses that can be targeted by pipeline drug companies.
Pipeline products can compete on safety, cost, efficiency, delivery, ' cosmetic
elegance' and reduced skin irritation
The FDA rejection of Intrinsa for FSD has left a big gap in the market.
Depending on the outcome of ongoing clinical trials, there are several
appealing inlicensing opportunities for larger companies wishing to unlock the
potentially lucrative US market
Reasons to Purchase
- Understand the placement of key compounds within the FSD development
pipeline
- Identify challenges to be met and niches to be filled in the FSD market
- Assess novel mechanisms of action in the early pipeline and their
potential for the treatment of FSD
View Cart
